Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in.

Next Previous
X
Search
Trial Profile

A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Cisplatin; Pemetrexed
  • Indications Malignant-mesothelioma
  • Focus Therapeutic Use
  • Acronyms DREAM

    • Most Recent Events

    • 01 Sep 2020 Primary endpoint (Progression free survival at 6 months (PFS6) according to mRECIST for MPM.) has been met according to the results published in the Lancet Oncology
    • 01 Sep 2020 Results evaluating the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma published in the Lancet Oncology
    • 03 Oct 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top